Skip to main content
padlock icon - secure page this page is secure

Hepatic Cytochrome P450 Regulation in Disease States

Buy Article:

$68.00 + tax (Refund Policy)

Hepatic cytochrome P450 (P450) enzyme activities and gene expression can be profoundly altered in disease states. In general the levels of affected hepatic P450 enzymes are depressed by diseases, causing potential and documented impairment of drug clearance and clinical drug toxicity. However, modulation of P450s is enzyme selective and this selectivity differs among different diseases. This review will concentrate on regulation of P450s in diabetes, obesity and infectious and inflammatory disease, conditions that affect millions of people worldwide every day.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: AhR-Regulated Genes; Aryl hydrocarbon receptor; CYP2E1; CYP4A; DIABETES AND OBESITY; Hepatic P450s; Hepatic cytochrome P450; INFLAMMATION AND INFECTION; Interferon; Interleukin; LIVER DISEASES; Napthoflavone; Nitric Oxide; Nitric oxide synthase; Onstitutive androstane receptor; Peroxisome proliferator activated receptor; Pregnane X receptor; Tumor necrosis factor

Document Type: Review Article

Publication date: June 1, 2001

More about this publication?
  • Current Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism and disposition. The journal serves as an international forum for the publication of timely reviews in drug metabolism. Current Drug Metabolism is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments. The journal covers the following areas:

    In vitro systems including CYP-450; enzyme induction and inhibition; drug-drug interactions and enzyme kinetics; pharmacokinetics, toxicokinetics, species scaling and extrapolations; P-glycoprotein and transport carriers; target organ toxicity and interindividual variability; drug metabolism and disposition studies; extrahepatic metabolism; phase I and phase II metabolism; recent developments for the identification of drug metabolites and adducts.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more